Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
Abstract Background Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. Methods We u...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-11-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3454 |
id |
doaj-e10d708d462749aabd8a2b7458fc7ad3 |
---|---|
record_format |
Article |
spelling |
doaj-e10d708d462749aabd8a2b7458fc7ad32020-11-25T03:36:30ZengWileyCancer Medicine2045-76342020-11-019218258826510.1002/cam4.3454Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factorGuoqiao Zheng0Kristina Sundquist1Jan Sundquist2Asta Försti3Akseli Hemminki4Kari Hemminki5Division of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg GermanyCenter for Primary Health Care Research Lund University Malmö SwedenCenter for Primary Health Care Research Lund University Malmö SwedenDivision of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg GermanyCancer Gene Therapy Group Translational Immunology Research Program University of Helsinki Helsinki FinlandDivision of Molecular Genetic EpidemiologyGerman Cancer Research Center (DKFZ) Heidelberg GermanyAbstract Background Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. Methods We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. Results Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. Conclusions Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification.https://doi.org/10.1002/cam4.3454cancer riskimmune suppressionmultiple cancersrisk factors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Guoqiao Zheng Kristina Sundquist Jan Sundquist Asta Försti Akseli Hemminki Kari Hemminki |
spellingShingle |
Guoqiao Zheng Kristina Sundquist Jan Sundquist Asta Försti Akseli Hemminki Kari Hemminki Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor Cancer Medicine cancer risk immune suppression multiple cancers risk factors |
author_facet |
Guoqiao Zheng Kristina Sundquist Jan Sundquist Asta Försti Akseli Hemminki Kari Hemminki |
author_sort |
Guoqiao Zheng |
title |
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_short |
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_full |
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_fullStr |
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_full_unstemmed |
Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
title_sort |
rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2020-11-01 |
description |
Abstract Background Many cancers are increased in immunosuppressed patients and evidence is accumulating that immune dysfunction may be a contributing risk factor for second primary cancers (SPCs). The aim of this study was to explore the potential influence of immune mechanisms in SPC. Methods We used the Swedish Cancer Registry (1990‐2015) to select 13 male and 14 female first primary cancers (FPCs) that are known to be related to immune suppression. We assessed relative risks (RRs) for any of these as concordant (same first and second cancer) and discordant FPC‐SPC pairs. Hierarchical clustering of significant RRs was performed for cancers as FPC and SPC. Results Concordant risks for SPCs were excessive in men and women for nasal (RRs 59.3 for men and 150.6 for women), tongue/mouth (51.7 and 100.8), and lip (32.4 and 61.2) cancers. Heatmaps showed that some cancers, such as skin cancer, tongue/mouth cancers, and non‐Hodgkin lymphoma had multiple bidirectional associations as FPC and SPC. Nasal cancer and chronic lymphocytic leukemia had associations mainly as FPC while liver and kidney cancers showed most associations as SPC. Conclusions Immune dysfunction may be a plausible contributing factor for most of the associations, which calls for experimental verification. |
topic |
cancer risk immune suppression multiple cancers risk factors |
url |
https://doi.org/10.1002/cam4.3454 |
work_keys_str_mv |
AT guoqiaozheng ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT kristinasundquist ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT jansundquist ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT astaforsti ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT akselihemminki ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor AT karihemminki ratedifferencesbetweenfirstandsecondprimarycancersmayoutlineimmunedysfunctionasakeyriskfactor |
_version_ |
1724549755493679104 |